#USA #Henderson #VolitionRx #Lung Cancer #Nu.Q® Cancer

Introduction

VolitionRx Limited, a pioneering company in the field of epigenetics, has recently unveiled an innovative report titled "Lung Cancer: Hope of a Brighter Tomorrow." This report highlights the groundbreaking potential of the Nu.Q® Cancer blood test, which aims to revolutionize early detection and monitoring strategies for lung cancer. As experts forecast this market to reach approximately $4 billion, VolitionRx stands on the cusp of something significant.

The Significance of Nu.Q® Cancer

The Nu.Q® Cancer assays have been rigorously developed with the primary objective of offering a cost-effective, minimally invasive solution for the early detection of lung cancer. This method promises ease of administration, requiring only a small volume of blood, making it not only user-friendly for patients but also practical from a logistical standpoint. Dr. Andrew Retter, Volition's Chief Medical Officer, expressed significant optimism about the report, highlighting the potential implications of integrating the Nu.Q® test into existing health care protocols.

Key Features of the Nu.Q® Test

The report underscores several compelling features of the Nu.Q® Cancer assay:

• - Integration with Current Treatments: It can be used alongside existing methods such as Low Dose Computed Tomography and Next Generation Sequencing (NGS), creating a robust framework for cancer detection and management.
• - Comprehensive Monitoring: The assay is designed not just for initial screening but also for continuous monitoring throughout the treatment process, potentially improving patient outcomes.
• - Retrospective Study Evidence: Importantly, the announcement coincides with the publication of data from a 1050-patient retrospective study on treatment-naïve Non-Small Cell Lung Cancer, emphasizing the real-world efficacy of the Nu.Q® tests.

Market Potential and Strategic Vision

Gael Forterre, Volition's Chief Commercial Officer, also elaborated on the significant financial prospects ahead. The global accessible market for lung cancer diagnosis and monitoring presents a unique opportunity for VolitionRx, with expectations set high for collaboration with leading diagnostic companies. Following strategic meetings, they aim to secure multiple licensing agreements for leveraging the Nu.Q® technology efficiently.

Additionally, Volition’s automated nucleosome assays promise compatibility with existing chemiluminescence platforms globally, reducing barriers to entry. This strategic positioning highlights VolitionRx's commitment to making the Nu.Q® Cancer tests broadly accessible through partnerships and licensing.

Looking Ahead

As the industry prepares for the European Lung Cancer Congress this March, Volition is gearing up to showcase these advancements and the supporting data in Paris. The company’s report serves as a crucial tool for informing health care professionals about the capabilities of the Nu.Q® assay and its potential to transform lung cancer diagnostics. The collaboration with teams like Hospices Civils de Lyon strengthens the foundation for a collective push towards better lung cancer management strategies.

Conclusion

VolitionRx is at the forefront of a crucial shift in cancer diagnostics. The Nu.Q® Cancer assays not only signify hope for improved lung cancer detection and management but also paint a bright future for the company's growth in the diagnostic landscape. Stakeholders are encouraged to download the full report, "Lung Cancer: Hope of a Brighter Tomorrow" for more in-depth insights and data.

Contact Information

For more information, consult the VolitionRx website or contact:

• - Media Inquiries: Louise Batchelor, email
• - Investor Relations: Jeremy Feffer, email

This strategic insight into the burgeoning potential of the Nu.Q® Cancer test not only offers promise to patients but also presents a lucrative business opportunity for VolitionRx in a critical segment of healthcare.